Palatin Technologies

382 articles about Palatin Technologies

• Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

  9/7/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that enrollment in the PL9643 MELODY-1 Phase 3 study in dry eye disease (DED) is complete, with 570 patients enrolled.

• Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/7/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.

• Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

  8/10/2023

  Palatin Technologies, Inc. today announced it has initiated a clinical development program evaluating bremelanotide, a melanocortin receptor 4 (MCR4) agonist, co-formulated with a PDE5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy.

• Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

  8/8/2023

  Palatin Technologies, Inc. today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China.

• Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®

  8/7/2023

  Palatin Technologies, Inc. today announced that it has entered a strategic partnership with UpScriptHealth, a leading direct-to-consumer telemedicine company providing telemedicine services to pharmaceutical and medical technology companies.

• Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference

  8/4/2023

  Palatin Technologies, Inc. today announced that management will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023.

• Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results

  7/11/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal fourth quarter ended June 30, 2023 Vyleesi® product revenue results.

• Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference

  5/30/2023

  Palatin Technologies, Inc. today announced the presentation of the poster "MC1R Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced Rat Model of Diabetic Nephropathy" at the International Podocyte Conference May 24-26, 2023 in Philadelphia, PA.

• Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

  5/16/2023

  Palatin Technologies, Inc. today announced financial results for its fiscal third quarter ended March 31, 2023.

• Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

  5/11/2023

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets.

• Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

  5/9/2023

  Palatin Technologies, Inc. today announced the presentation of the poster "Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases" at the Digestive Disease Week annual meeting May 6-9, 2023 in Chicago, Illinois.

• Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar

  5/8/2023

  Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, hosted a key opinion leader webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye Disease.

• Palatin Technologies to Host Key Opinion Leader Webinar

  5/1/2023

  Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a key opinion leader webinar on May 8, 2023 at 11:00 a.m. ET.

• Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference

  4/27/2023

  Palatin Technologies, Inc. today announced the presentation of a poster entitled Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.

• Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma

  4/25/2023

  Palatin Technologies, Inc. today announced the presentation of a poster entitled, Melanocortin Receptor Agonist PL9588 Reduces Intraocular Pressure in Normotensive Rabbits at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.

• Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results

  4/19/2023

  Palatin Technologies today announced preliminary fiscal third quarter ended March 31, 2023 Vyleesi® product revenue results.

• Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences

  4/18/2023

  Palatin Technologies, Inc. today announced The International Journal of Molecular Sciences published a manuscript, "Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina" by Tat Fong Ng and Andrew W. Taylor from Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, in Boston, Massachusetts.

• Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease

  3/2/2023

  Palatin Technologies, Inc. today announced Frontiers in Immunology published a manuscript, "A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs and humans." 

• Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension

  2/28/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension."

• Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

  2/15/2023

  Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2022.